Neumora Therapeutics COO Aurora disposes of $269,966 in stock By Investing.com

Daljit Singh Aurora, Chief Operating and Development Officer at Neumora Therapeutics, Inc. (), engaged in a series of stock transactions on August 20 and 21, 2026. Mr. Aurora disposed of 176,060 shares of common stock, totaling approximately $269,966. The shares were sold at prices ranging from $1.48 to $1.6393. These dispositions followed the acquisition of an equal number of shares through option exercises, valued at approximately $126,763 at an exercise price of $0.72 per share. The transactions come as NMRA stock trades at $1.63, down significantly from its 52-week high of $3.65, with the stock posting a -51.92% return over the past six months. According to InvestingPro analysis, the company remains slightly undervalued at current levels.

On August 20, Mr. Aurora directly sold 67,741 shares at a weighted average price of $1.5144. Additional sales on the same day included 66,711 shares sold indirectly through the Aurora Family Trust, at a weighted average price of $1.514. On August 21, Mr. Aurora directly sold 20,553 shares at a weighted average price of $1.5949, and indirectly sold 21,055 shares through the Aurora Family Trust at a weighted average price of $1.5958.

The shares sold were acquired through the exercise of stock options. On August 20, Mr. Aurora directly acquired 67,741 shares and indirectly acquired 21,685 shares and 45,026 shares through the Aurora Family Trust, all at an exercise price of $0.72 per share. On August 21, he directly acquired an additional 20,553 shares and indirectly acquired 21,055 shares, also at $0.72 per share. The Aurora Family Trust holds shares for the benefit of Mr. Aurora’s immediate family.

Separately, on August 20, Mr. Aurora was granted 200,000 stock options with an exercise price of $1.52 per share. These options are scheduled to vest over a four-year period, with 25% vesting on the first anniversary of the grant date and the remainder vesting monthly thereafter. For deeper insights into NMRA’s financial health and comprehensive analysis, investors can access the full Pro Research Report, available exclusively on InvestingPro for this and 1,400+ other US equities.

In other recent news, Neumora Therapeutics announced that its Phase 3 KOASTAL-2 and KOASTAL-3 studies for the treatment of major depressive disorder with navacaprant did not meet their primary or key secondary endpoints. Consequently, the company decided to discontinue the development of navacaprant. Following this announcement, Needham lowered its price target for Neumora to $5 from $8, maintaining a Buy rating, while H.C. Wainwright reduced its target to $7 from $18 but also kept a Buy rating. Mizuho adjusted its price target down to $4 from $6, maintaining an Outperform rating. Additionally, Neumora reported favorable results from a 13-week rat toxicology study of NMRA-215, an oral NLRP3 inhibitor for obesity and cardiometabolic disease, with no unexpected adverse findings. H.C. Wainwright reiterated a Buy rating with a $7 price target following this positive development. The company also announced a 35% workforce reduction to align with its revised focus as a mid-stage biotech firm. These updates reflect significant shifts in the company’s strategic direction and analyst expectations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.